<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29231094</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>02</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>378</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.</ArticleTitle>
        <Pagination>
          <StartPage>615</StartPage>
          <EndPage>624</EndPage>
          <MedlinePgn>615-624</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1711948</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Low-molecular-weight heparin is the standard treatment for cancer-associated venous thromboembolism. The role of treatment with direct oral anticoagulant agents is unclear.</AbstractText>
          <AbstractText Label="METHODS">In this open-label, noninferiority trial, we randomly assigned patients with cancer who had acute symptomatic or incidental venous thromboembolism to receive either low-molecular-weight heparin for at least 5 days followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin at a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group). Treatment was given for at least 6 months and up to 12 months. The primary outcome was a composite of recurrent venous thromboembolism or major bleeding during the 12 months after randomization, regardless of treatment duration.</AbstractText>
          <AbstractText Label="RESULTS">Of the 1050 patients who underwent randomization, 1046 were included in the modified intention-to-treat analysis. A primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P=0.006 for noninferiority; P=0.87 for superiority). Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%) in the dalteparin group (difference in risk, -3.4 percentage points; 95% CI, -7.0 to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6).</AbstractText>
          <AbstractText Label="CONCLUSIONS">Oral edoxaban was noninferior to subcutaneous dalteparin with respect to the composite outcome of recurrent venous thromboembolism or major bleeding. The rate of recurrent venous thromboembolism was lower but the rate of major bleeding was higher with edoxaban than with dalteparin. (Funded by Daiichi Sankyo; Hokusai VTE Cancer ClinicalTrials.gov number, NCT02073682 .).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Raskob</LastName>
            <ForeName>Gary E</ForeName>
            <Initials>GE</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>van Es</LastName>
            <ForeName>Nick</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Verhamme</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carrier</LastName>
            <ForeName>Marc</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Nisio</LastName>
            <ForeName>Marcello</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garcia</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grosso</LastName>
            <ForeName>Michael A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kakkar</LastName>
            <ForeName>Ajay K</ForeName>
            <Initials>AK</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kovacs</LastName>
            <ForeName>Michael J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mercuri</LastName>
            <ForeName>Michele F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meyer</LastName>
            <ForeName>Guy</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Segers</LastName>
            <ForeName>Annelise</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Minggao</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Tzu-Fei</ForeName>
            <Initials>TF</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeo</LastName>
            <ForeName>Erik</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zwicker</LastName>
            <ForeName>Jeffrey I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Weitz</LastName>
            <ForeName>Jeffrey I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Büller</LastName>
            <ForeName>Harry R</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>From the University of Oklahoma Health Sciences Center, College of Public Health, Oklahoma City (G.E.R.); the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam (N.E., H.R.B.), and ITREAS, Academic Research Organization (A.S.) - both in Amsterdam; the Department of Vascular Medicine and Hemostasis, University Hospitals Leuven, Leuven, Belgium (P.V.); Ottawa Hospital Research Institute, Ottawa (M.C.), London Health Sciences Centre-Victoria Hospital, London, ON (M.J.K.), University Health Network, University of Toronto, Toronto (E.Y.), and McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON (J.I.W.) - all in Canada; the Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy (M.D.N.); the Department of Medicine, Division of Hematology, University of Washington, Seattle (D.G.); Daiichi Sankyo Pharma Development, Basking Ridge, NJ (M.A.G., M.F.M., M.S., G.Z.); Thrombosis Research Institute and University College London, London (A.K.K.); the Department of Respiratory Disease, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris (G.M.); the Department of Internal Medicine, Division of Hematology, Ohio State University Wexner Medical Center, Columbus (T.-F.W.); and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.I.Z.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <CollectiveName>Hokusai VTE Cancer Investigators</CollectiveName>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT02073682</AccessionNumber>
              <AccessionNumber>NCT02073682</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D000073843">Equivalence Trial</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NDU3J18APO</RegistryNumber>
          <NameOfSubstance UI="C552171">edoxaban</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S79O08V79F</RegistryNumber>
          <NameOfSubstance UI="D017985">Dalteparin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2018 Feb 15;378(7):673-674</RefSource>
          <PMID Version="1">29443673</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Intern Emerg Med. 2018 Oct;13(7):1089-1091</RefSource>
          <PMID Version="1">29948831</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>BMJ Evid Based Med. 2018 Dec;23(6):230</RefSource>
          <PMID Version="1">29959155</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2018 Jul 05;379(1):93</RefSource>
          <PMID Version="1">29975029</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2018 Jul 05;379(1):93-4</RefSource>
          <PMID Version="1">29975031</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2018 Jul 05;379(1):94</RefSource>
          <PMID Version="1">29975032</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2018 Jul 05;379(1):94-5</RefSource>
          <PMID Version="1">29975033</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>MMW Fortschr Med. 2021 Dec;163(21-22):82</RefSource>
          <PMID Version="1">34888823</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017985" MajorTopicYN="N">Dalteparin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <InvestigatorList>
        <Investigator ValidYN="Y">
          <LastName>Beyer-Westendorf</LastName>
          <ForeName>Jan</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Boda</LastName>
          <ForeName>Zoltan</ForeName>
          <Initials>Z</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chlumsky</LastName>
          <ForeName>Yaromir</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gibbs</LastName>
          <ForeName>Harry</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kamphuizen</LastName>
          <ForeName>P W</ForeName>
          <Initials>PW</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Monreal</LastName>
          <ForeName>Manuel</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ockleford</LastName>
          <ForeName>Paul</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pabinger-Fasching</LastName>
          <ForeName>Ingrid</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Sinnaeve</LastName>
          <ForeName>Peter</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Beenen</LastName>
          <ForeName>Ludo</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gerdes</LastName>
          <ForeName>Victor</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Laleman</LastName>
          <ForeName>Wim</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Larrey</LastName>
          <ForeName>Dominiqe</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>van Mechelen</LastName>
          <ForeName>Rob</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Roos</LastName>
          <ForeName>Yvo</ForeName>
          <Initials>Y</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Scheerder</LastName>
          <ForeName>Maeke</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Slagboom</LastName>
          <ForeName>Ton</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Thijs</LastName>
          <ForeName>Vincent</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Eikelboom</LastName>
          <ForeName>John W</ForeName>
          <Initials>JW</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Crowther</LastName>
          <ForeName>Mark</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Roberts</LastName>
          <ForeName>Robin S</ForeName>
          <Initials>RS</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Vanassche</LastName>
          <ForeName>Thomas</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Vandenbriele</LastName>
          <ForeName>Christophe</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Debaveye</LastName>
          <ForeName>Barbara</ForeName>
          <Initials>B</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dani</LastName>
          <ForeName>Vidhi</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Schwocho</LastName>
          <ForeName>Lee</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Duggal</LastName>
          <ForeName>Anil</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Baker</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Carroll</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chan</LastName>
          <ForeName>N</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Coughlin</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Crispin</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gallus</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hugman</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tran</LastName>
          <ForeName>H</ForeName>
          <Initials>H</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Brodmann</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mathies</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rossmann</LastName>
          <ForeName>D</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Deeren</LastName>
          <ForeName>D</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Hainaut</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Jochmans</LastName>
          <ForeName>K</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Vercauter</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wautrecht</LastName>
          <ForeName>J-C</ForeName>
          <Initials>JC</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Champion</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gross</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lee</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Shivakumar</LastName>
          <ForeName>S</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tagalakis</LastName>
          <ForeName>V</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zed</LastName>
          <ForeName>E</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kovarova</LastName>
          <ForeName>K</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lastuvka</LastName>
          <ForeName>J</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Matoska</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Prosecky</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Achkar</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Aquilanti</LastName>
          <ForeName>S</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Chatellain</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cony-Makhoul</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Del Piano</LastName>
          <ForeName>F</ForeName>
          <Initials>F</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Elias</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Falvo</LastName>
          <ForeName>N</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ferrari</LastName>
          <ForeName>E</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mahé</LastName>
          <ForeName>I</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Merle</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mismetti</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Muron</LastName>
          <ForeName>T</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pernod</LastName>
          <ForeName>G</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Quere</LastName>
          <ForeName>I</ForeName>
          <Initials>I</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Schmidt</LastName>
          <ForeName>J</ForeName>
          <Initials>J</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Stephan</LastName>
          <ForeName>D</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Espinola-Klein</LastName>
          <ForeName>C</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Horacek</LastName>
          <ForeName>T</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kröning</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Oettler</LastName>
          <ForeName>W</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Schellong</LastName>
          <ForeName>S</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Schön</LastName>
          <ForeName>N</ForeName>
          <Initials>N</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Zwemmrich</LastName>
          <ForeName>C</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Farkas</LastName>
          <ForeName>K</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gurzo</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Nyirati</LastName>
          <ForeName>G</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Pecsvarady</LastName>
          <ForeName>Z</ForeName>
          <Initials>Z</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Riba</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Becattini</LastName>
          <ForeName>C</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cattaneo</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Falanga</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ghirarduzzi</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Imberti</LastName>
          <ForeName>D</ForeName>
          <Initials>D</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Lodigiani</LastName>
          <ForeName>C</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Parisi</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Porreca</LastName>
          <ForeName>E</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Squizzato</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Tassoni</LastName>
          <ForeName>M I</ForeName>
          <Initials>MI</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Villalta</LastName>
          <ForeName>S</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Visonà</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Beeker</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Boersma</LastName>
          <ForeName>W</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Brouwer</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Dees</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Huisman</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Kuijer</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Mairuhu</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Meijer</LastName>
          <ForeName>K</ForeName>
          <Initials>K</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Middeldorp</LastName>
          <ForeName>S</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Otten</LastName>
          <ForeName>H M</ForeName>
          <Initials>HM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>van Marwijk-Kooy</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>van Wissen</LastName>
          <ForeName>S</ForeName>
          <Initials>S</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Westerweel</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Harper</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Merriman</LastName>
          <ForeName>E</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ockelford</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Royle</LastName>
          <ForeName>G</ForeName>
          <Initials>G</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Smith</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Cereto Castro</LastName>
          <ForeName>F</ForeName>
          <Initials>F</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>de Oña Navarrete</LastName>
          <ForeName>R</ForeName>
          <Initials>R</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Font Puig</LastName>
          <ForeName>C</ForeName>
          <Initials>C</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gallardo Díaz</LastName>
          <ForeName>E</ForeName>
          <Initials>E</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Garcia-Bragado Dalmau</LastName>
          <ForeName>F</ForeName>
          <Initials>F</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Ruiz Artacho</LastName>
          <ForeName>P</ForeName>
          <Initials>P</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Santamaria</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Baumann Kreuziger</LastName>
          <ForeName>L</ForeName>
          <Initials>L</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>De Sancho</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Gaddh</LastName>
          <ForeName>M</ForeName>
          <Initials>M</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Metjian</LastName>
          <ForeName>A</ForeName>
          <Initials>A</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Rojas Hernandez</LastName>
          <ForeName>C M</ForeName>
          <Initials>CM</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Shah</LastName>
          <ForeName>V</ForeName>
          <Initials>V</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Smith</LastName>
          <ForeName>W</ForeName>
          <Initials>W</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Wun</LastName>
          <ForeName>T</ForeName>
          <Initials>T</Initials>
        </Investigator>
        <Investigator ValidYN="Y">
          <LastName>Xiang</LastName>
          <ForeName>Z</ForeName>
          <Initials>Z</Initials>
        </Investigator>
      </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29231094</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMoa1711948</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
